OPEN MEETING AGENDA
Delta Chelsea, Toronto. Room: Churchill A
Friday April 27, 2012 ~ 13.30pm – 16.30pm
Chair: Dr. Kim Chi
IND Program Directors: Drs. Elizabeth Eisenhauer and Lesley Seymour

1:30 pm: Welcome  
Dr. Kim Chi

1:30 pm: **Background on MET inhibitors in the clinic** (20’) 
IND.197 foretinib in Triple Negative Breast Cancer (5’)  
Dr. Percy Ivy, NCI CTEP  
IND.198 foretinib + lapatinib HER2 + breast cancer phase I trial (5’)  
Dr. Danny Rayson  
IND.196 foretinib + erlotinib NSCLC phase I (5’)  
Dr. Stephen Chia

2:05 pm  **Challenges in Combining Targeted Agents**  
Dr. Lesley Seymour

2:25 pm  IND. 195: SB939 prostate cancer - Final clinical and CTC results (10’)  
Dr. Kim Chi

2:35 pm  COFFEE/TEA

2:55 pm  IND.203 Pediatric phase I trial of SB939 (10’)  
Dr. Sylvain Baruchel

3:05 pm  IND.199 Temsirolimus cervix – final clinical and translational data (10’)  
Dr. Anna Tinker

3:15 pm  **Mutational analysis of mTOR inhibitor endometrial trials (IND.160 A, B and IND.192)**  
Dr. Amit Oza

3:30 pm  IND.204 PX866 in Glioblastoma: Interim report (10’)  
Dr. Marshall Pitz

3:40 pm  **Report on April 26 2012 NCIC CTG workshop: Addressing Strategies in Personalized Medicine**  
Dr. Janet Dancey

4:10 pm  Update on ongoing and planned IND trials

4:30 pm  ADJOURN

**IND OPEN COMMITTEE MEETING OBJECTIVES**

- To summarize aspects of recent developments in the understanding of molecular biology and therapeutics as these relate to specific malignancies and their therapeutic targets
- To describe and discuss results of recent Investigational New Drug studies conducted by the NCIC Clinical Trials Group
- To understand aspects new clinical trial methodologies in the field of early cancer drug development